Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apotransferrin in Atransferrinemia Patients
NCT01797055Phase 2Active, not recruiting
- Sponsor
- Prothya Biosolutions
- Start
- Dec 2010
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of apotransferrin in congenital atransferrinemia (CAT), sponsored by Prothya Biosolutions. Started Dec 2010; status: active, not recruiting.
02
Drugs
apotransferrin
03
Conditions
congenital atransferrinemia (CAT)
Beyond the preview
Go deeper on NCT01797055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01797055.